NCT00865475View on ClinicalTrials.gov

Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
HIV InfectionHIV Infections
Interventions
DRUG

AZT+3TC+ABV (Trizivir)

Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy

DRUG

Switching to LPV/r monotherapy (Kaletra)

Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r

Trial Locations (7)

20014

Hospital de Donostia, Donostia / San Sebastian

28041

Hospital Doce de Octubre, Madrid

28046

Hospital La Paz, Madrid

28700

Hospital Ntra.Sra. de Zumarraga, Zumarraga

28911

Hospital Severo Ochoa, Leganés

48013

Hospital de Basurto, Bilbao

Unknown

H. Son Dureta, Mallorca

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT00865475 - Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC | Biotech Hunter | Biotech Hunter